Q-omics provides the consensus-scored GPR176-DT profile across patient tissues and cancer cell-line models. GPR176-DT expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GPR176-DT is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, GPR176-DT RNA expression shows 14,549 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KICH, and UVM as cancer lineages where GPR176-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR176-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR176-DT survival associations across molecular data types. GPR176-DT RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR176-DT RNA expression–survival associations across cancer types. High GPR176-DT expression shows unfavorable associations in HNSC, BRCA, DLBC, ACC, KICH and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GPR176-DT RNA expression.
This table summarizes GPR176-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for GPR176-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR176-DT shows lower tumor expression in KICH, THCA and KIRC and higher tumor expression in HNSC, LUSC and LUAD. The KICH box plot shows higher GPR176-DT RNA expression in normal versus tumor tissue (log2 FC = −0.115, t-test p < 0.001).
This table shows molecular features associated with GPR176-DT in patient tissues and cancer cell lines. In patient samples, GPR176-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR176-DT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and NCI60_ALL.
